Literature DB >> 21136012

Cardiovascular risk assessment in haemophilia patients.

Sara Biere-Rafi1, Manuel A Baarslag, Marjolein Peters, Marieke J H A Kruip, Roderik A Kraaijenhagen, Martin Den Heijer, Harry R Büller, Pieter W Kamphuisen.   

Abstract

Haemophilia patients have a reduced cardiovascular mortality, which may be the result of a lifelong deficiency of factor VIII or IX. On the other hand, the prevalence of risk factors may differ in these chronically ill patients compared to the general population. The prevalence of risk factors and expected risk of cardiovascular disease was compared in haemophilia patients and healthy controls. In adult haemophilia A and B patients, body mass index, blood pressure, cholesterol levels and fasting glucose levels were measured and compared to healthy age-matched males. The expected risk of mortality due to cardiovascular disease was calculated using a European risk prediction algorithm (SCORE). A total of 100 haemophilia A and B patients and 200 healthy controls were analysed. The mean age of the patients was 47 years (range 18-83). The number of haemophiliacs with hyperglycaemia (24%) and hypertension (51%) was higher than in the controls (p-values 0.001 and 0.03, respectively). The mean low-density lipoprotein (LDL) cholesterol level in cases was lower than the controls (3.02 mM (0.69-6.57) and 3.60 mM (1.68-5.95), respectively, p < 0.001). Fewer cases had increased LDL levels (p=0.045). No difference was found in the 10-year cardiovascular mortality risk >10% between cases and controls (12% and 7%, respectively, p = 0.18). The prevalence of risk factors and expected risk of cardiovascular disease in haemophilia patients is comparable to the general population. This strengthens the hypothesis that hypocoagulability may reduce cardiovascular mortality in haemophilia patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21136012     DOI: 10.1160/TH10-07-0460

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  14 in total

Review 1.  Current concepts in the management of stable ischemic heart disease and acute coronary syndrome in patients with hemophilia.

Authors:  Ahmad Y Jabbar; Hassan Baydoun; Maissaa Janbain; Keith C Ferdinand
Journal:  Ann Transl Med       Date:  2018-08

Review 2.  How I treat patients with inherited bleeding disorders who need anticoagulant therapy.

Authors:  Karlyn Martin; Nigel S Key
Journal:  Blood       Date:  2016-04-22       Impact factor: 22.113

Review 3.  Intracranial haemorrhage in children and adults with haemophilia A and B: a literature review of the last 20 years.

Authors:  Ezio Zanon; Samantha Pasca
Journal:  Blood Transfus       Date:  2018-02-04       Impact factor: 3.443

4.  Off-pump technique and replacement therapy for coronary artery bypass surgery in a patient with hemophilia B.

Authors:  M Fernández-Caballero; M F Martinez; G Oristrell; N Palmer; A Santamaría
Journal:  J Thromb Thrombolysis       Date:  2019-08       Impact factor: 2.300

5.  Prevalence and risk factors for hypertension in hemophilia.

Authors:  Annette von Drygalski; Nicholas A Kolaitis; Ricki Bettencourt; Jaclyn Bergstrom; R Kruse-Jarres; Doris V Quon; Christina Wassel; Ming C Li; Jill Waalen; Darlene J Elias; Laurent O Mosnier; Matthew Allison
Journal:  Hypertension       Date:  2013-04-29       Impact factor: 10.190

6.  A cross-sectional analysis of cardiovascular disease in the hemophilia population.

Authors:  Suman L Sood; Dunlei Cheng; Margaret Ragni; Craig M Kessler; Doris Quon; Amy D Shapiro; Nigel S Key; Marilyn J Manco-Johnson; Adam Cuker; Christine Kempton; Tzu-Fei Wang; M Elaine Eyster; Philip Kuriakose; Annette von Drygalski; Joan Cox Gill; Allison Wheeler; Peter Kouides; Miguel A Escobar; Cindy Leissinger; Sarah Galdzicka; Marshall Corson; Crystal Watson; Barbara A Konkle
Journal:  Blood Adv       Date:  2018-06-12

Review 7.  Consensus review of the treatment of cardiovascular disease in people with hemophilia A and B.

Authors:  Victor A Ferraris; Leonard I Boral; Alice J Cohen; Susan S Smyth; Gilbert C White
Journal:  Cardiol Rev       Date:  2015 Mar-Apr       Impact factor: 2.644

8.  A second retrospective database analysis confirms prior findings of apparent increased cardiovascular comorbidities in hemophilia A in the United States.

Authors:  Thomas J Humphries; Alice Ma; Craig M Kessler; Rajesh Kamalakar; Jennifer Pocoski
Journal:  Am J Hematol       Date:  2016-04-07       Impact factor: 10.047

9.  The Hypertension of Hemophilia Is Not Explained by the Usual Cardiovascular Risk Factors: Results of a Cohort Study.

Authors:  Richard F W Barnes; Thomas J Cramer; Afrah S Sait; Rebecca Kruse-Jarres; Doris V K Quon; Annette von Drygalski
Journal:  Int J Hypertens       Date:  2016-11-14       Impact factor: 2.420

10.  BAY 81-8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years.

Authors:  Johnny Mahlangu; Maria Fernanda Lopez Fernandez; Elena Santagostino; Shadan Lalezari; Despina Tseneklidou-Stoeter; Horst Beckmann; Nikki Church
Journal:  Eur J Haematol       Date:  2020-03-23       Impact factor: 2.997

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.